bumetanide / Generic mfg. - LARVOL DELTA

IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED MINIMAL CHANGE DISEASE - A CASE OF SUCCESSFUL RECHALLENGE (ISN-WCN 2026) - "After progression on carboplatin and paclitaxel, she was subsequently started on pembrolizumab, and demonstrated clinical response after three cycles, the last given 2 weeks before presentation...Given the temporal association and favorable oncologic response to ICI therapy, the diagnosis of MCD was attributed to pembrolizumab.ICI therapy was discontinued, and the patient was treated with oral prednisone 60 mg daily (tapered over 24 days) and rituximab (anti-CD20 antibody) 1 g IV given 2 weeks apart. Supportive therapy included bumetanide 1 g IV twice daily, losartan 12.5 mg daily, and atorvastatin 10 mg daily...In two cases, MCD relapsed following ICI re-challenge while in the third case, MCD remission was maintained with daily low-dose prednisone. Here, we report the first successful ICI re-challenge in a patient with ICI-associated MCD using a short course of low-dose prednisone bridging, achieving sustained renal remission and durable anti-tumor response."

Checkpoint inhibition • Clinical • CNS Disorders • Dyslipidemia • Endometrial Cancer • Glomerulonephritis • Immunology • Oncology • Solid Tumor

Efficacy of Furosemide-Albumin Compared to Bumetanide in Critically Ill Patients (SCCM 2026) - "In critically ill patients requiring diuresis, continuous infusion of bumetanide resulted in a comparable urine output to continuous furosemide-albumin infusion. These findings suggest that bumetanide may be an effective alternative for fluid management in this patient population."

Clinical • Glomerulonephritis • Nephrology • Renal Disease

Safety and Efficacy of Bumetanide Infusion in a Single-Center Pediatric Intensive Care Unit (SCCM 2026) - "Furosemide continuous infusions (FD) often provide suboptimal results. BD was well tolerated with FD-comparable adverse effects. Longer length of stay and ventilator dependence in the BD group were plausibly related to initial FD failure, yet BD achieved target diuresis eventually. These findings support BD as a safe alternative, with potential utility as a first-line diuretic in select PICU populations."

Clinical • Critical care • Nephrology • Pediatrics • Renal Disease

Furosemide vs Bumetanide in Congestive Heart Failure (CHF): Should We Consider a Stepwise Approach? (SCCM 2026) - "There was no significant statistical difference in rates of hospital readmissions and mortality with either drug, as with previous literature. However, it can be concluded that Furosemide, due to its cost-effectiveness, can be used as a first-line treatment, followed by Bumetanide (in a step-wise manner) due to its better bioavailability in advanced heart failure or diuretic resistance. A patient-centered approach should be used when determining the use of diuretics."

Cardiovascular • Congestive Heart Failure • Heart Failure

Chloride homeostasis dysfunction drives hyperactivation of corticotropin-releasing factor-expressing neurons in the amygdala in stress-induced hypertension. (PubMed, J Clin Invest) - "NKCC1 inhibition with bumetanide restored GABAergic inhibition and chloride homeostasis, normalized neuronal excitability, leading to reduced sympathetic vasomotor tone in CUMS BHRs. These results indicate that NKCC1-mediated disruption of chloride homeostasis in CeA CRF-expressing neurons contributes to elevated sympathetic activity and hypertension under chronic stress. These findings enhance our understanding of the neuronal and molecular mechanisms underlying stress-induced hypertension and reveal potential targets for its prevention and treatment."

Journal • Cardiovascular • Hypertension • SLC12A2

A RARE PRESENTATION OF BUMETANIDE INDUCED DRESS SYNDROME (ACC 2026) - "Common triggers include anticonvulsants, allopurinol, and antibiotics, while loop diuretic-associated cases are exceedingly rare...Bumetanide was started 2 weeks before admission, briefly replaced with furosemide; symptoms recurred upon re-initiation... DRESS is challenging to recognize in patients on multiple medications, making careful review of new drugs and dose changes essential. Diagnosis may be supported by drug cessation and re-challenge. This patient had started bumetanide 2 weeks prior to admission; although DRESS typically occurs 2-6 weeks after exposure, delayed onset is possible."

Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Dyslipidemia • Eosinophilia • Heart Failure • Hepatology • Hypertension • Immunology • Inflammation • Nephrology • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

IMPACT OF SEVERE HYPOALBUMINEMIA ON LENGTH OF STAY AND DIURETIC USE IN PATIENTS HOSPITALIZED FOR ACUTE DECOMPENSATED HEART FAILURE (ACC 2026) - "IV bumetanide use was more frequent in severe HA, vs mild HA, and normal albumin (11.3%, 6.0%, and 7.4% respectively) but the difference was not statistically significant... Severe HA (<2.5 g/dL) in patients hospitalized with heart failure is associated with longer LOS, higher IV loop diuretic requirements, and greater need for thiazide augmentation. Severe hypoalbuminemia, but not milder hypoalbuminemia, may predict diuretic response and hospitalization outcomes. Further studies may reveal that serum albumin may be useful to guide initial therapeutic strategies."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

WHEN DIGIFAB ISN'T ENOUGH: SUCCESSFUL RESCUE WITH PLASMAPHERESIS IN SEVERE DIGOXIN TOXICITY (ACC 2026) - "Case: An 81 y/o woman with HFpEF, PAF, and HTN was treated at an outside hospital for ADHF and AF with RVR and later discharged home on digoxin 0.25 mg daily, amiodarone 200 mg twice daily, and bumetanide 1 mg twice daily. Plasmapheresis may serve as a rescue therapy in severe digoxin toxicity with renal failure."

Cardiovascular • Renal Disease

PERCUTANEOUS VENTRICULAR ASSIST DEVICE HEMOLYSIS CAUSING DIALYSIS-DEPENDENT ACUTE KIDNEY INJURY: A DUAL SIGNAL CASE (ACC 2026) - "Management focused on rapid de-escalation and explant, preload/afterload optimization (dobutamine 5 μg/kg/min; nitroprusside), and aggressive decongestion (bumetanide infusion with chlorothiazide). Even brief pVAD support can trigger severe hemolysis and AKI, particularly with low PAPi and high pump demand. Vigilant waveform surveillance, the lowest effective P-level, proactive RV/preload optimization, and early de-escalation/removal may mitigate hemolysis-related renal injury."

Clinical • Acute Kidney Injury • Cardiovascular • Hematological Disorders • Nephrology • Pulmonary Disease • Renal Disease • HP

ACUTE RV SHOCK AFTER TRANSCATHETER TRICUSPID VALVE REPLACEMENT (ACC 2026) - "Inhaled epoprostenol (50 ng/kg/min) was added to decrease PVR...Intermittent IV bumetanide was used to achieve a CVP of 10-12 mmHg... The patient improved clinically and hemodynamically. After 36 hours of hemodynamic stability, vasoactive agents were weaned in sequence—vasopressin, then dobutamine, followed by epoprostenol. All vasoactives were off by post-procedure day 4 and the patient was discharged by day 6."

Cardiovascular • Metabolic Disorders • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

HIGH-OUTPUT HEART FAILURE: A CASE OF WET BERIBERI (ACC 2026) - "A bumetanide infusion was started... Clinicians should be aware of the potential risk of thiamine deficiency in those with a grain-based diet and the association with wet beriberi as a cause of high-output heart failure and excessive edema."

Clinical • Acute Kidney Injury • Carcinoid Syndrome • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Hematological Disorders • Hepatology • Immunology • Nephrology • Obesity • Pulmonary Disease • Renal Disease • Respiratory Diseases • Solid Tumor

Minimizing in Source Fragmentation for Mass Spectrometry Based NDSRI Analytical Procedures: A Case Study of Nitroso-bumetanide. (PubMed, AAPS J) - "Thus, here, we present a case study on an NDSRI (nitroso-bumetanide) to illustrate how efforts can be taken during analytical procedure development to minimize ISF while still achieving the analytical target profile (ATP) measurement goals. In addition, we share some thoughts about incorporating risk assessment and leveraging prior knowledge for analytical procedure development for NDSRI LC-MS technology-based testing purposes."

Journal

A Clinical Spiral: BRASH Syndrome in an Elderly Patient with Chronic Kidney Disease (NKF-SCM 2026) - "Home medications were carvedilol, dapagliflozin, spironolactone, valsartan, bumetanide, and atorvastatin...The patient was given a warming blanket, intravenous fluids, atropine, epinephrine, and transcutaneous pacing...CONCLUSION This case illustrates the hallmark features and typical patient profile of BRASH syndrome. The patient’s rapid recovery after withholding AV nodal blocking agents, providing hemodynamic support, and initiating renal replacement therapy underscores the importance of timely identification and targeted management of each component of the syndrome."

Clinical • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Heart Failure • Hypertension • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Bumetanide‑blocked SLC12A2 exerts a protective effect in experimental diabetic retinopathy. (PubMed, Int J Mol Med) - "Furthermore, SLC12A2 deficiency ameliorated DR progression in streptozotocin‑induced diabetic mice by improving retinal thickness and pathological changes. The present study elucidates the crucial role of bumetanide in DR treatment and suggests that targeting SLC12A2 may represent a novel therapeutic strategy for the prevention of DR."

Journal • Diabetes • Diabetic Retinopathy • Inflammation • Metabolic Disorders • Retinal Disorders • ICAM1 • IL1B • MMP2 • MMP9 • SLC12A2 • VCAM1

In brief: A second subcutaneous furosemide infusor (Lasix ONYU) for heart failure. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

A Shift in the Loop: Innovative Outpatient Diuretic Strategies for Worsening Heart Failure (NKF-SCM 2026) - "More recently, two novel outpatient approaches have emerged: the at-home use of subcutaneous furosemide (SCF) and bumetanide nasal spray (BNS)...Despite these encouraging findings, data on the use of these two approaches remain limited. Large clinical trials are needed to address important knowledge gaps regarding their optimal application."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial. (PubMed, BMJ Open) - P2 | "In accordance with Regulation (EU) 536/2014 for pharmacological interventional trials, the study was subsequently transitioned to the Clinical Trials Information System (EU CT No 2024-519342-71-00), with the initial record entered on 23 December 2024, and the transition authorised on 3 February 2025 (https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-519342-71-00). EudraCT 2015-005780-16."

Journal • CNS Disorders • Cognitive Disorders • Developmental Disorders • Genetic Disorders • Mental Retardation • Pediatrics

Proinflammatory cytokines modify Ca2+ signaling and induce an apoptotic lipidome in murine small intestinal organoids. (PubMed, Front Physiol) - "Stimulation of Cl- secretion seems to underly this swelling since it was inhibited by bumetanide, a blocker of Na+-K+-2Cl- cotransporters. Ca2+ imaging experiments revealed that the cytokine mix time-dependently enhanced the response to carbachol, a Ca2+-dependent secretagogue, which would favor Ca2+-dependent Cl- secretion...AP-SMALDI MSI showed an accumulation of ceramide-positive (apoptotic) cells within the organoid lumen. Proinflammatory cytokines induce fluid secretion and transiently upregulate Ca2+ signaling concomitant with the induction of an apoptotic lipidome in small intestinal organoids."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology • CASP3 • IFNG • IL1B • TNFA

A Novel Cardiac Diuretic Responsiveness Index Predicts Acute Kidney Injury After Adult Cardiac Surgery (STS 2026) - "Results Of 1795 patients, 93.1% received furosemide and 6.9% received bumetanide as the initial diuretic. The CDRI offers early insight into renal functional status, providing a window for timely intervention. Table Image"

Clinical • Surgery • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Nephrology • Renal Disease

Inhibition of Astrocyte Swelling Mitigates Spreading Depolarization and Excitotoxicity in Ischemic Brain Tissue (ISC 2026) - "To counteract astrocyte swelling Bumetanide (Bum; 1 mM), TGN-020 (100 µM), and DCPIB (20 µM) were applied to inhibit sodium potassium chloride cotransporter 1 (NKCC1), aquaporin-4 (AQP4) and volume regulated anion channels (VRAC). In HM60 the SD area affected nearly the entire cortex (82.5±11.5%) which was reduced by DCPIB and TGN-020+Bum treatments (45.1±11.6 and 44.8±13.2%)... Our results indicate that astrocyte swelling enhances SD propagation and glutamate excitotoxicity in a stroke-related cytotoxic edema model. Pharmacological inhibition of astrocyte swelling may help limit secondary injury and slow lesion progression during the acute phase of ischemic stroke."

Cardiovascular • CNS Disorders • Ischemic stroke

Glutamate load fosters spreading depolarization under osmotic stress in brain slices. (PubMed, Front Cell Neurosci) - "Astrocyte swelling was reduced by blocking AQP4+NKCC1 (TGN-020 + bumetanide) and VRAC channels (DCPIB), while neuronal NMDA and AMPA/kainate receptors were antagonized with MK-801 + CNQX. Both astrocytic and neuronal interventions disrupted typical SD initiation patterns, producing atypical, multifocal SD events. These findings demonstrate that astrocyte volume regulation and neuronal ionotropic glutamate receptors jointly shape SD characteristics under osmotic stress, identifying astrocytic water/ion homeostasis and glutamatergic signaling as potential therapeutic targets to limit excitotoxic injury in acute cerebrovascular disease."

Journal • Cardiovascular • CNS Disorders • Ischemic stroke • Vascular Neurology

BumxAD: Bumetanide in Patients With Alzheimer's Disease (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Stanford University | Trial completion date: Apr 2025 ➔ Dec 2026 | Trial primary completion date: Apr 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders

Sodium-potassium-chloride cotransporter 1 as a novel regulator of DAMPs-mediated alveolar epithelial-macrophage crosstalk in LPS-induced lung inflammation. (PubMed, Biochem Pharmacol) - "To address this, we employed A549 lung epithelial cells and RAW264.7 murine macrophages stimulated with lipopolysaccharide (LPS) in the presence or absence of the NKCC1 inhibitor bumetanide...These findings demonstrate that LPS-induced DAMPs release from epithelial cells drives macrophage activation through inflammatory signaling, while NKCC1 inhibition effectively suppresses these pathways. This study suggests that NKCC1 may act as a regulator of DAMPs-mediated AEC-macrophage interactions."

Journal • Acute Lung Injury • Infectious Disease • Inflammation • Oncology • Pneumonia • Respiratory Diseases • Septic Shock • CGAS • HMGB1 • MAPK8 • TLR2 • TNFA

Drug Development. (PubMed, Alzheimers Dement) - "The inclusion criteria include mild cognitive impairment or mild dementia due to AD, AD medications are planned to remain stable throughout, willingness and ability to complete all aspects of the study including assessments, neuropsychological testing, and MRI. Exclusion criteria includes clinically significant abnormalities in screening laboratory tests, chronic liver disease, renal insufficiency, poorly managed hypertension and participants taking the following concomitant medications, based on the current Prescribing Information for bumetanide: lithium, drugs with ototoxic potential, drugs with nephrotoxic potential, probenecid, and indomethacin We present the clinical trial protocol and design for a phase II trial evaluating the effect of bumetanide in AD."

Clinical • Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Hepatology • Hypertension • Nephrology • Renal Disease • APOE

Drug Development. (PubMed, Alzheimers Dement) - "Evidence from real-world data, patient iPSC-derived cellular and brain organoids, and in vivo transgenic mouse model observations suggest that sildenafil is a potential repurposable treatment for AD. However, future clinical trials are necessary to test and confirm the causal relationship of sildenafil in prevention and treatment of AD."

Journal • Alzheimer's Disease • CNS Disorders • p-tau181